From Biomarker Change to Target Engagement
A concentration-related biomarker change can support the claim that a drug is interacting with its target, but the strength of that claim depends on what the biomarker measures. A validated assay that measures drug-bound target provides more direct evidence than a downstream change that could arise through several biological steps. Even direct evidence in blood cells does not, by itself, establish engagement of the same target in a different tissue.
The key is to connect the measured response to a defined quantity. For target occupancy, that quantity is the fraction of target molecules bound by drug. A concentration–occupancy curve can indicate concentrations at which engagement is increasing or approaching a plateau. Interpreting such a curve as evidence of engagement requires both an appropriate model and a measurement that genuinely reflects binding.
The Equilibrium Occupancy Relationship
For a single drug binding reversibly to one class of target sites, a standard equilibrium model relates occupancy to the free drug concentration at the target. Let \(C_u\) be the unbound drug concentration at the target and \(K_D\) the equilibrium dissociation constant, expressed in the same concentration units. The model is
This relationship assumes that binding is at equilibrium; the target sites are equivalent and independent; binding is reversible and noncooperative; and \(C_u\) is the local free concentration available to bind the target. It also assumes that the occupancy assay measures bound target in a way that is not materially distorted by sample handling or assay interference. If these conditions do not hold, the equation may be a poor description of the data or its parameters may not have the intended interpretation.
The equation follows from the definition of \(K_D\). For the binding reaction \(D+T\rightleftharpoons DT\), where \(D\) is free drug, \(T\) is unbound target, and \(DT\) is drug–target complex, \(K_D=[D][T]/[DT]\). With free drug concentration \(C_u=[D]\), rearrangement gives \([DT]/[T]=C_u/K_D\). Total target is \([T]+[DT]\), so
At \(C_u=K_D\), the model predicts \(\theta=0.5\). This does not make \(K_D\) a universal clinical concentration threshold: it is a binding parameter under the model’s conditions, whereas the concentration at a particular tissue may differ from measured plasma concentration. If the concentration is expressed in nM, \(K_D\) must also be expressed in nM.
For a desired occupancy fraction \(q\), solving the equation for concentration gives \(C_u=qK_D/(1-q)\). Thus 80% occupancy requires \(4K_D\), and 90% requires \(9K_D\), under the same model assumptions. These are model-based concentrations, not proof that an observed biomarker has reached that occupancy.
Worked Example: Calculating Occupancy at Several Concentrations
Suppose a hypothetical direct occupancy assay is considered valid for a target in blood cells, and the estimated \(K_D\) is 3.0 nM. Assume equilibrium and that the stated concentrations are unbound concentrations at the measured target. Calculate predicted occupancy at 1.0, 3.0, and 9.0 nM.
At 1.0 nM,
or 25.0% occupancy. At 3.0 nM,
or 50.0%. At 9.0 nM,
or 75.0%. The model therefore predicts increasing engagement over this range, but 9.0 nM is not near complete saturation: one quarter of measured target remains unoccupied in the model. These predictions describe the measured blood-cell target, not necessarily a target in another tissue.
When a Biomarker Is Not an Occupancy Measurement
Many biomarkers change because target binding alters a pathway, cell function, or downstream mediator. Such a response may be useful evidence of pharmacological activity, but it is not automatically a direct measurement of the fraction of targets bound. A common empirical model for an increasing drug-induced response is
Here \(\Delta R(C)\) is the change in the biomarker from its reference level, \(E_{\max}\) is the maximum modeled change, and \(EC_{50}\) is the concentration giving half of that maximum change. This model assumes the response is adequately described by a saturating concentration relationship over the studied range. Its \(EC_{50}\) is a response parameter; it equals \(K_D\) only under additional conditions linking measured response directly and proportionally to occupancy. Signal amplification, limited downstream capacity, baseline effects, or the assay’s measurement scale can separate the two.
A useful distinction is between a fraction of the modeled maximum response and a fraction of target occupied. For the equation above, the concentration giving fraction \(q\) of \(E_{\max}\) is \(C=qEC_{50}/(1-q)\). For example, the modeled response reaches 90% of its own maximum at \(9EC_{50}\). This is not a claim of 90% target occupancy unless the biomarker has been validated to support that interpretation.
Worked Example: Interpreting a Downstream Biomarker Curve
In a hypothetical study, a downstream biomarker has a baseline value of 12 units. A fitted concentration–response model estimates a maximum drug-induced increase of 78 units and an \(EC_{50}\) of 2.5 ng/mL. Calculate the predicted biomarker value at 10 ng/mL and the concentration giving 90% of the maximum increase.
At 10 ng/mL, the modeled increase is
Adding the baseline gives a predicted value of \(12+62.4=74.4\) units. The increase is 80.0% of the modeled maximum, since \(62.4/78=0.800\). It does not follow that 80.0% of target is occupied: this is a downstream biomarker, and the fitted maximum and \(EC_{50}\) describe its response.
For 90% of the modeled maximum increase, solve \(C=0.90(2.5)/(1-0.90)=22.5\) ng/mL. At that concentration, the predicted increase is \(78(0.90)=70.2\) units, giving a total biomarker value of \(82.2\) units. The calculation identifies a model-based response landmark, not an occupancy threshold.
Assessing the Evidence and Its Scope
The interpretation should match the measurement. Direct assays of drug-bound target, when validated for the relevant sample and concentration range, can estimate occupancy more directly. A binding assay may characterize affinity under its assay conditions, but its \(K_D\) does not by itself establish in vivo occupancy. A downstream pharmacodynamic biomarker can show a concentration-related biological response, but additional evidence is needed to attribute that response specifically to target binding. These methods answer related but distinct questions.
| Measurement | What it can support | Key interpretive limit |
|---|---|---|
| Direct target-occupancy assay | Fraction of measured target bound in the sampled material | Assay validity and sampled compartment determine what target is represented |
| Binding assay | Binding affinity under the assay’s conditions | In vitro affinity is not itself in vivo tissue occupancy |
| Downstream biomarker | Drug-related biological response, if the design and measurement support that inference | Response magnitude is not automatically a fraction of target occupied |
A practical interpretation also depends on time and compartment. A sample collected before drug and target binding have approached equilibrium may not reflect the equilibrium curve. Total plasma concentration is not necessarily the free concentration at the target. Tissue penetration, local binding, transport, target abundance, and binding kinetics can all make target-site concentration or engagement differ from a peripheral measurement. A blood-cell occupancy result is evidence about the assayed blood-cell target at the sampled time; it is not direct evidence of brain, tumor, or other tissue occupancy.
Worked Example: Why Peripheral Occupancy Does Not Establish Tissue Occupancy
Consider a hypothetical drug with \(K_D=2.0\) nM in two compartments. At the sampling time, the unbound concentration is 8.0 nM in blood cells but 0.50 nM at a target in a protected tissue. Assume, only for this calculation, that the same \(K_D\) and equilibrium model apply in both compartments.
For the blood-cell target,
or 80.0% occupancy. For the protected-tissue target,
or 20.0%. Thus the same drug can produce substantial peripheral engagement while producing much lower engagement at a tissue target, because the local unbound concentrations differ. The calculation does not establish that actual tissue occupancy is 20.0%; it illustrates why peripheral measurement alone cannot answer that question. Tissue-specific exposure and measurement evidence would be needed.
Common Pitfalls and Practical Checks
A concentration–response curve is most informative when the measurement, concentration, and biological interpretation are aligned. Before describing a biomarker as target-engagement evidence, check whether the assay distinguishes bound from unbound target, whether nonspecific signal or sample processing could alter the result, and whether the sample time is appropriate for the binding process. Confirm that the concentration used is relevant to the target compartment and that its units and free-versus-total status are clear.
A plateau in an observed curve can be consistent with saturating engagement, but it can also arise from a ceiling in the assay or downstream biology. Conversely, a biomarker that has not plateaued within the observed range does not identify a saturation concentration. These are limits on what can be concluded from the available measurements, not reasons to force an occupancy interpretation onto an indirect response.
- Mistake: “The downstream response is 80% of its maximum, so target occupancy is 80%.” Correction: It is 80% of the modeled response maximum. Occupancy requires a direct measurement or a validated link between response and binding.
- Mistake: “Blood occupancy is high, so the target in the brain is highly occupied.” Correction: Blood data support a claim about the sampled blood compartment; tissue exposure and target engagement may differ.
- Mistake: “The fitted \(EC_{50}\) is the binding \(K_D\).” Correction: They are different parameters unless the response model and measurement justify equating them.
Check Your Understanding
Answer each question, then compare your reasoning with the solutions below.
- Under a one-site equilibrium occupancy model, what occupancy is predicted when the local unbound concentration is \(3K_D\)?
- A downstream biomarker has \(EC_{50}=4.0\) mg/L. What concentration gives 75% of its modeled maximum response, and does that establish 75% occupancy?
- A validated direct occupancy assay reports 60% occupancy in circulating cells. What does this establish, and what does it not establish about a tissue target?
- Why might a fitted biomarker \(EC_{50}\) differ from the binding \(K_D\)? Give one reason.
Solutions. (1) \(\theta=3K_D/(K_D+3K_D)=3/4=0.750\), or 75.0% occupancy, if the model assumptions hold. (2) \(C=0.75(4.0)/(1-0.75)=12.0\) mg/L. This is 75% of the modeled maximum response, not evidence of 75% occupancy by itself. (3) It supports 60% occupancy of the measured circulating-cell target at the sampled time, subject to assay validity; it does not establish occupancy in a different tissue. (4) A downstream pathway can amplify or limit the response relative to binding, so the concentration producing half-maximal biomarker change need not be the concentration producing half occupancy.